The U.S. next generation sequencing market size was valued at USD 2.85 billion in 2025 and is predicted to hit around USD ...
"In our study, we showed that fine needle aspiration (FNA) biopsy material can be a good source for next-generation sequencing (NGS) for patients with metastatic prostate cancer. Based on these ...
Belfast-based biotech company Biomarx has raised £700,000 in pre-seed funding to progress the development of a diagnostics ...
Biomarker Therapy in 2025: More Lung Cancer Options, Competition in New Drug Classes, ctDNA Advances
This year, there was a surge of new lung cancer treatments, more options for patients with earlier-stage disease, and growing evidence on the utility of ctDNA testing.
The race for early cancer detection is one that physicians have been running for millennia. In one of humanity’s oldest surviving medical texts, the ancient Egyptian physician Imhotep described 46 ...
Mr. Han may continue to purchase the Company’s ADSs through open-market transactions, privately negotiated transactions or block trades, or other legally permissible means, depending on market ...
The global companion diagnostics market is projected to grow at a robust CAGR of approximately 13% through 2031. This growth is driven by the increasing demand for personalized medicine, continuous ...
Life sciences and diagnostics company Revvity has had a busy couple of years, playing a major role in the next-generation sequencing-based screening of newborns to better enable healthcare ...
The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted therapies, the promise of off-the-shelf chimeric antigen receptor (CAR) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback